Navigation Links
Lytix Presents LTX-109 Anti-Microbial Data at ICAAC
Date:11/20/2008

f Tromso the Company has access to state-of-the-art laboratories and staff with extensive experience of developing peptide based drugs, including preparation of peptidomimetics. Business and product development is driven from the subsidiary office in Oslo.

   http://www.lytixbiopharma.com

    Corporate Inquiries:

    Anders Fugelli
    Head of Business Development
    Lytix Biopharma AS
    P.O. Box 6447, Tromso Research Park
    N-9294 Tromso, Norway

    Tel +47-924-81-432
    Email: anders.fugelli@lytixbiopharma.com


'/>"/>
SOURCE Lytix Biopharma AS
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
2. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
3. Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
4. Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
5. Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207
6. Topical Treatment for Cold Sores Achieves Efficacy of Oral Drugs; Represents Paradigm Shift in the Treatment of Skin Infections
7. Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference
8. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
9. Mpex Pharmaceuticals Presents New Data on MP-376 in Cystic Fibrosis
10. Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium
11. Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... IRVINE, Calif., Aug. 4, 2015  Syneron Medical Ltd. (NASDAQ: ... announced financial results for the three month period ended June ... Recent Non-GAAP 1 Highlights: , ... constant currency. , North American product sales grew 45% ... in constant currency, including 14% product growth in the EMEA ...
(Date:8/3/2015)...   The Intellectual Property and Science business ... of intelligent information for businesses and professionals announced ... R&D Factbook , the biopharmaceutical industry,s leading resource ... in R&D, the analysis identifies a surge in ... forecasts sales to reach $1.3 trillion by 2018. ...
(Date:8/3/2015)... GLENWOOD, Ill. , Aug. 3, 2015  Landauer, ... personal and environmental radiation measurement and monitoring, outsourced medical ... announced it will release financial results for the fiscal ... August 10, 2015. The Company will ... August 11, 2015 at 9:00 a.m. Central Time (10:00 ...
Breaking Medicine Technology:Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 2Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 3Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 4Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 5Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 6Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 7Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 8Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 9Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 10Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 11Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 12Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 13Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 14Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 15Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 16Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 17Pharma Sales to Grow Beyond $1 Trillion 2Landauer, Inc. Announces Date And Time For Announcement Of Fiscal Third Quarter 2015 Results And Conference Call 2
... Feb. 1, 2011 Anthera Pharmaceuticals, Inc. (Nasdaq: ... treat serious diseases associated with abnormal auto-immune responses and ... Thompson to its Board of Directors. Currently, Dr. Thompson ... founder and Managing Director of Strategicon Partners, an investment ...
...  China Medicine Corporation (OTC Bulletin Board: ... and distributor of Western pharmaceuticals, traditional Chinese medicines ... Republic of China, today announced that the Company ... Ministry of Agriculture ("MOA") for the Company,s proprietary ...
Cached Medicine Technology:Dr. Peter Thompson Joins Anthera Pharmaceuticals Board of Directors 2China Medicine Corporation Receives Manufacturing License for rADTZ 2China Medicine Corporation Receives Manufacturing License for rADTZ 3
(Date:8/4/2015)... ... August 04, 2015 , ... Wimbledon Health Partners , ... NCV testing, announced their collegiate division, Wimbledon U , continues to not ... program at a time. , “Wimbledon U welcomes the eight new ...
(Date:8/4/2015)... ... ... An article published July 27th by the Providence Journal detailed ... people to lose weight. Specifically the study compared control patients with those who were ... financial incentive to the overall incentive of increased health. According to Michael Feiz, M.D., ...
(Date:8/4/2015)... , ... August 04, 2015 , ... Bayco Products, Inc. ... enough to fit, for example, on hard hats that have a flip-up face shield. ... allows users to work without having to remove their headlamp when raising or ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... suffering from underarm sweat. Evolutions Medical & Day Spa in Santa Barbara, CA ... only non-invasive, FDA cleared treatment that permanently eliminates sweat and odor glands in ...
(Date:8/4/2015)... ... August 04, 2015 , ... Worldwide Power Products acquires new ... its reach in Texas. Effective July 1st of this year, Worldwide Power Products ... With the North Texas acquisition, Worldwide Power Products (“WPP”) now services 1000 ...
Breaking Medicine News(10 mins):Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 3Health News:Article on Incentivizing Weight Loss Mirrors Similar Motivations Surrounding Weight Loss Surgery, Says Dr. Feiz & Associates 2Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 2Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 3Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 3Health News:North Texas Acquisition Press Release 2
... named REACH: Registration, Evaluation and Authorization of Chemicals, has shifted ... manufacturers. ,The chemical companies would be bound by ... of their business. ,This law aims to make ... safe for users and the environs. ,The European ...
... Surgical Adjuvant Breast and Bowel Project (NSABP) B-33 ... Cancer Symposium, showed that// postmenopausal women with hormone ... years of tamoxifen were 56% less likely to ... who received placebo (P=0.004). ,“Aromasin provided ...
... in occupational settings and in the environment has been ... Journal of Occupational and Environmental Medicine, official publication of ... is a special issue providing updates on particles and ... types of studies for some particles in terms of ...
... soy-based substance. A US based study finds: BBIC improves ... multiple// sclerosis. ,A group of animals with ... animals also suffering from the same disease received a ... to walk, while those that didn't get the drug ...
... the Bombay Hospital and three other firms are planning to ... ,The Jaipur Development Authority would allot land for the five ... a Rs.2 billion Medi-City to be built here in three ... ,The state plans to be strict with the investors ...
... In the absence of vaccine against HIV/AIDS, the 'social vaccine' ... of the deadly virus, a top UN official here said ... to fight against the HIV/AIDS," said Peter Piot, executive director ... vaccine I mean to create a mass awareness to educate ...
Cached Medicine News:Health News:New Study Shows Efficacy of AROMASIN on Early Breast Cancer 2Health News:New Study Shows Efficacy of AROMASIN on Early Breast Cancer 3Health News:New Study Shows Efficacy of AROMASIN on Early Breast Cancer 4Health News:Inhaled Particles Increases the Risk of Lung Cancer 2
... detects the presence of Hemoglobin S ... of reconstituted solubility buffer and 20l of ... cell hemoglobin control. Each test kit contains ... two buffer dispensing caps and two vials ...
... Streck Cytometry Concentrate is for use ... by flow cytometry. Each 70ml bottle of ... fluid with distilled water. Compared to Cubitainers, ... usable space and saves money without compromising ...
... is an assayed control for monitoring immunophenotyping ... accuracy and reproducibility of all the steps ... red blood cell lysis. Reference values for ... B lymphocytes, granulocytes, monocytes, and NK cells. ...
Use Streck-Sheath to count and classify white blood cells on the Abbott CELL-DYN® 3000, 3500 and 3700. The shelf life is two years from date of manufacture...
Medicine Products: